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1. Introduction 
Immune response is a universal and evolutionarily conserved mechanism of host defense 
against infection. It is the first line of defense found in all multicellular organisms and is 
adaptive only in vertebrates (Medzhitov, 1997). 
The body responds to tissue injury through two different defense systems, the innate (non-
specific or non-adaptive) and adaptive (specific) immune system. The adaptive immune 
response is highly specific and has a memory which helps the system to remember the 
invading agent but the innate immune system is an evolutionary rudiment whose only 
function is to contain the infection regardless of the type of invading pathogen until the 
“real” immune response can kick in. Adaptive immunity developed because of the 
inflexibility of the nonclonal receptors used by the innate immune response.  It uses 
receptors and effectors that are ancient in their lineage and must provide protection against 
a wide variety of pathogens. Defects in innate immunity are very rare and almost always 
lethal. 
 
Adaptive immune system Innate immune system Property 
Encoded in gene segments 
Rearrangement necessary 
Fixed in genome 
Rearrangement is not necessary 
Receptors 
Clonal 
   All cells of a class distinct 
Non-clonal 
   All cells of a class identical 
Distribution 
Details of molecular structure 
   (Proteins, peptides, carbohydrates) 
Conserved molecular patterns    
   (LPS, LTA, mannans, glycans) 
Recognition 
Imperfect: Selected in individual somatic 
   cells 
Perfect: Selected over 
   evolutionary time 
Self-Nonself 
discrimination 
Delayed activation of effectors Immediate activation of effectorsAction time 
Clonal expansion or anergy 
IL-2 
Effector cytokines (IL-4, INFǄ) 
Co-stimulatory molecules 
Cytokines (IL1ǃ, IL-6) 
Chemokines (IL-8)
Response 
Table 1. Innate and adaptive immunity 
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Some of the consequences of the innate immune response are sodium and water retention in 
response to hypovolaemia, aldosterone  and ADH release, pyrexia (elevation of body 
temperature by 1 to 4° C) for 24-48 hours, increase energy expenditure, increase glucose and 
fat turnover, breakdown of adipose tissue as principal energy source, decrease in iron 
concentration, activation of monocytes and macrophages, catabolism of skeletal muscle to 
provide amino acid for gluconeogenesis and synthesis of acute-phase proteins. The 
properties of innate and adaptive immune systems are compared in Table 1. 
Increased expression of MHC class I related genes is demonstrated in hepatocytes after LPS 
treatment proposing as indicative of a possible link between innate and adaptive immune 
response (Yoo and Desiderio, 2003). 
In the CNS, cytokines induce a cascade of events which potentiate the cytokine-induced 
response, so favouring the appearance of the three hallmarks of the APR, namely fever, 
leucocytosis and changes in the concentration of serum acute phase proteins (APPs). In 
addition, the stimulation of the CNS results in activation of a variety of responses, mostly 
mediated by the hypothalamo– pituitary–adrenal and hypothalamo–pituitary–gonadal axes, 
inducing behavioural changes such as including lethargy, anorexia, adipsia and a disinterest 
in social and sexual activities (Paltrinieri 2007). 
Some of the factors modifying the response to injury include: severity of injury, nature of 
injury/infection, genetic factors, nutritional status, and coexisting diseases (Paltrinieri 2007). 
Inflammation can be classified into two categories: acute and chronic. Acute inflammation is 
a highly regulated defense mechanism of immune system possessing two well-balanced and 
biologically opposing arms termed apoptosis (‘Yin’) and wound healing (‘Yang’) processes. 
Unresolved or chronic inflammation (oxidative stress) is perhaps the loss of balance 
between ‘Yin’ and ‘Yang’ that would induce co-expression of exaggerated or ‘mismatched’ 
apoptotic and wound healing factors in the microenvironment of tissues. Unresolved 
inflammation could initiate the genesis of many age-associated chronic illnesses such as 
autoimmune and neurodegenerative diseases or tumors/cancers (Khatami, 2009). As it is in 
the Daoism theory Yin and Yang can change in to one another. 
The term “acute phase” was introduced in 1941 to describe serum in which C-reactive 
protein was present (Petersen et al., 2004). 
Acute phase response (APR), an evolutionary conserved and nonspecific response, refers to 
a series of complex physiological events occurring shortly after a tissue injury, inflammation 
and infections, infection, trauma, malignant neoplasms, burns, tissue infarction, 
immunologically mediated inflammatory states, crystal-induced inflammatory states (gout), 
strenuous exercise, childbirth, and marked psychological stress (Hirvonen, 2000). 
The purpose of the APR is to prevent further injury of an organ, to limit the growth of the 
infective organism, to remove harmful molecules, and to activate the repair processes to 
return the organ to normal function (Hirvonen 2000). APR is mediated by cytokines and 
signaling molecules which are produced and secreted by hepatocytes, macrophages, 
fibroblasts, and epithelial cells (Burgess-Beusse and Darlington, 1998). They are able to 
release a broad spectrum of inflammatory mediators, such as cytokines, lipid mediators, 
vasoactive amines, products of the complement and coagulation cascades, proteases, 
reactive oxygen species, and nitric oxide (Hirvonen, 2000). 
These inflammatory mediators set off both the local and systemic inflammatory processes. 
Activated macrophages release a broad spectrum of mediators of which cytokines appear to 
be uniquely important in initiating the next series of reactions (Koj, 1996).  
www.intechopen.com
 
Acute Phase Proteins – Analysis, Clinical Applications and Potentials 
 
353 
Cytokines which act as the messengers between the local site of injury and hepatocytes, 
have different sources and functions and are present in mammals, birds, fish, and reptiles 
and starfish (Peterson et al., 2004). 
At the reactive site, cytokines act on stromal cells, including fibroblast and endothelial cells, 
to cause a secondary wave of cytokines. This secondary wave augments the homeostatic 
signal and initiates the cellular and cytokine cascades involved in the complex process of the 
APR (Baumann and Gauldie, 1994).  
The synthesis and release of plasma APP from liver is regulated by inflammatory mediators. 
These mediators fall into four major categories: interleukin-6-type cytokines, interleukin-1-
type cytokines, glucocorticoids, and growth factors. Cytokines mainly stimulate the APP 
gene-expression, while glucocorticoids and growth factors function more as modulators of 
cytokine action (Baumann & Gauldie 1994). Interleukin-6 (IL-6) has been recognized as the 
principal regulator of most APP genes (Hirvonen 2000). 
The cytokines act in a synergistic manner: TNF-ǂ mobilizes peripheral amino acids by 
activating a proteolytic process in muscles, thus increasing the molecules available for the 
liver to synthesize new proteins. IL-1 is a key element in modulating hepatic protein 
synthesis since it has an inhibitory effect on the synthesis of negative APPs and, by contrast 
a stimulatory activity on the synthesis of positive APPs (Paltrinieri, 2007). 
This latter effect depends also on a permissive action of glucocorticoids. 
 
 
Fig. 1. Summary of the mechanisms responsible for the clinical signs and laboratory findings 
in the acute phase reaction (circled by the thick line). Solid lines indicate stimulatory effects; 
dashed lines indicate inhibitory effects. IL-1, interleukin-1; TNF-a, tumour necrosis factor a; 
IL-6, interleukin-6; CRF, corticotrophin releasing factor; GnRH, gonadotropin releasing 
hormone; LH, luteinising hormone; FSH, follicle stimulating hormone; ACTH, 
adrenocorticotropic hormone; APP, acute phase protein (Paltrinieri, 2007). 
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Finally, IL-6 facilitates the release of APPs in blood (Ceciliani et al., 2002). This complex 
pattern of induction is defined as ‘type I response’ but some APPs are induced mainly by IL-
6, according to a ‘type II response’ (Petersen et al., 2004). 
There are two categories of APP genes based on their cytokine responsiveness. Type 1 genes 
respond to IL-1, IL-6, tumor necrosis factor alpha (TNF-ǂ), and glucocorticoids, while type 2 
genes respond to IL-6 and glucocorticoids but not IL-1 or TNF-ǂ (Burgess-Beusse B.L. and 
Darlington G.J., 1998). Some authors categorize the pro-inflammatory cytokines into two 
major groups with respect to acute phase protein induction, namely IL-1 type cytokines 
(including IL-1ǂ, IL-1ǃ, TNF-ǂ, TNF-ǃ, etc ) and IL-6 type cytokines (including IL-6, 
oncostatin M, IL-11, leukemia inhibitory factor, oncostatin M, cardiotrophin-1, etc) acting 
through different receptors located on the membrane of the hepatocytes. IL-1 type cytokines 
elicit a primary autostimulatory signal stimulating the release of a secondary cytokine 
signal, IL-6 type cytokines, in various cell types (Mackiewicz, 1997) (Fig 1). 
IL-6 type cytokines also seem to exert a negative feed-back on the production of IL-1 type 
cytokines (Petersen et al., 2004). IL-6 is released by many cells when they are injured. ǃ –
adrenergic agonists also can enhance IL-6 release from stimulated cells (Munford, 2000). 
These cytokines all elicit similar responses because of the association of their respective 
individual receptors with a common membrane-spanning signal-transduction molecule, gp 
130 (Uhlar and Whitehead, 1999). Serum concentrations of cytokines increase during hours 
after stimulation (Petersen et al., 2004) and would be cleared from blood soon. Cytokines 
mainly stimulate the APP gene-expression, while glucocorticoids and growth factors 
function more as modulators of cytokine action (Baumann & Gauldie 1994). 
Hepatocytes have a high density of cytokine receptors per cell, and the liver has the largest 
number of cells with receptors, making it a primary organ involved in the APR. In response 
to cytokines, changes in expression of various acute-phase protein (APP) genes occur, with 
an up regulation of positive APP genes (those genes whose expression increases during the 
APR) and a down regulation of negative APP genes (genes whose expression decreases 
during the APR). The protein products of these genes are secreted from hepatocytes and, in 
combination with the effects of the cytokines themselves, bring about the systemic and 
metabolic changes seen in response to inflammation. These changes include clinical, 
systemic inflammatory signs as fever, inappetite and depression, which are reflections of 
multiple endocrinological, haematological, immunological, metabolic and neurological 
changes in the diseased animal (Stadnyk and Gauldie, 1991). 
2. Acute phase proteins (reactants) 
One of the main phenomena during the APR is the production of acute phase proteins 
(APPs) (Baumann and Gauldie, 1994). APPs play a role in the defense response of the host. 
Monitoring the blood concentrations of APPs can provide information on the progression of 
the inflammatory reaction (Kent, 1992). The APR may result in changes in more than 200 
proteins grouped as either positive APP or negative APP (Cray et al., 2009). 
It has been proposed that the term ‘acute phase protein’ should be replaced with ‘acute 
phase reactant’. The two terms are generally considered to be synonymous, but the latter 
would also include non-protein molecules such as total serum syalic acid, which increases 
during inflammation, or proteins involved in APRs but traditionally considered separately 
from APPs, such as the same APR-inducing cytokines or hormones ghrelin, leptin, and 
gonadotropins, the concentrations of which vary during APR (Paltrinieri, 2007). Here we use 
the more common nomenclature (acute phase proteins, since only the classical APPs are 
discussed). 
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Interleukin-6 (IL-6) has been recognized as the principal regulator of most APP genes. The 
APPs produced are termed type-2 APPs; in most species these  include fibrinogen (Fb), 
haptoglobin (Hp) and at least one of the major antiproteases, like ǂ1-proteinase inhibitor 
(ǂ1-PI). The group of APP genes regulated by interleukin-1-type  cytokines  (IL-1a,  IL-1b, 
TNFǂ) is clearly different from that regulated by IL-6-type cytokines. The APP produced are 
called type-1 APP, and they include alpha1-acid glycoprotein (ǂ1-AG), serum amyloid-A 
(SAA), and C-reactive protein (CRP), depending on the species. 
Binding of the inflammatory mediators to their respective receptors on hepatocytes and 
transduction of this signal induce changes in APP gene expression that are primarily 
regulated at a transcriptional level. Under certain conditions post-transcriptional 
mechanisms, translation, APP modelling and export, may also be involved in this process 
(Kushner 1993, Pannen & Robotham 1995). Some APPs are also produced extrahepatically, 
e.g. ǂ1-PI, ceruloplasmin (Cp), complement components, and SAA (Raynes 1994). 
By definition, APPs are proteins which their serum concentrations change by >25% in 
esponse to inflammation or infection (Eckersall and Bell, 2010). The APPs can be divided 
into minor, moderate and major APPs depending on their increase in concentration 
(Eckersall, 2000; Peterson, et al., 2004) (Table 2).  
 
Major APP (10-100 fold increase) Haptoglobin (Hp)Serum amyloi-A (SAA)
Moderate APP (2-10 fold increase)  ǂ1- acid glycoprotein (ǂ1-AG)ǂ1- proteinase inhibitor (ǂ1-PI) 
Minor APP (1-5 fold increase)  
Fibrinogen
Ceruloplasmin  
ǂ2- macroglobulin (ǂ2-M) 
complement component 3 (C3) 
Bovine lipopolysaccharide binding protein (bLBP) 
Table 2. Illustration of bovine plasma APP according to their responsivity during APR 
(Hirvonen, 2000). 
A major APP has a low serum concentration (<1 µg/L) in healthy animals and rises 
significantly by 100-1000 fold on stimulation, peaking at 24-48 h and then declining rapidly 
during the recovery phase. Moderate APPs increase some 5-10-fold on activation, peak after 
2-3 days, and decrease more slowly than major APPs. Minor APPs gradually increase by 
between 50% and 100% of its initial level. Negative APPs include albumin, transferrin and 
retinol binding protein which apart from albumin, their use in veterinary medicine is not 
common (Eckersall and Bell, 2010).  
This way of classifying positive APPs partly overlap since in many cases the protein that most 
frequently increases in a given species also shows a higher magnitude of increases compared 
to other species. The important concept is that each animal species has its own ‘major’ APP(s) 
that must be considered the marker of choice for diagnostic purposes (Table 3). 
The serum concentration of the rapid reacting APPs (such as SAA and CRP), which  are 
primarily induced by IL-1 type cytokines, increases within four hours (Petersen et) and 
return to the normal levels rapidly. Type 2 APPs (fibrinogen and haptoglobin in most 
species) are characterized by a latter increase in serum concentration remaining up to two 
weeks (Petersen  et al., 2004). The above mentioned classification is not  complete: bovine 
Hp is stimulated  by IL-6 and TNF, but not by IL-1 (Nakagawa-Tosa et al. 1995). 
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The group of positive APPs tends to increase continuously with the inclusion of newly 
discovered molecules, such as hepcidin, a protein involved in regulating iron metabolism 
during inflammation (Nemeth et al., 2003; Fry et al., 2004), or of molecules that are involved 
in processes different from inflammation but that are characterised by the typical ‘APP 
behaviour’ (e.g. showing an increase of >25% during inflammation). This is the case with 
antithrombin III, which may work as an APP in cats (Paltrinieri, 2007). 
 
 
*Normal level as well as acute phase concentration changes of SAP differ strongly between different 
mouse strains. ?: Nothing has been reported about the reaction of the protein indicated in the literature. 
NEG: Decrease in concentration (10-30%); 0: No change; I: 50% to 100% increase; II: Between 100% and 
10 time increase; III: More than 10 times increase (Petersen et al., 2004). 
Table 3. Acute phase proteins in different species. 
The APP  profiles  vary among  different  animal  species  (Kushner  1982, Hayes  1994)  and 
also within them. The profiles can be affected e.g. by age, sex, pregnancy, and 
polymorphism (Alsemgeest et al. 1993, Hayes 1994). Table 4 shows the physicochemical 
properties and reference intervals of different APP responders in some animal species.  
 
 
EF, electrophoretic migration; MW, molecular weight; g/dL, physiological concentration in serum; 
Group: proteins are listed according to the usual increase during the acute phase reaction (APR): I = 
increase up to 100%, II = increase up to 10·, III = increase >10· during APR. Major or Minor = species in 
which each APP is considered major or minor based on the frequency of increase during APR and on 
the magnitude of elevation (see I, II and III above); B = bovine; C = canine; E = equine; F = feline; H = 
human; M = mouse; S = swine; R = rat (Paltrinieri, 2008). 
*Modified from Gruys and Toussaint (2001) and Petersen et al. (2004).  
Table 4. Summary of physico-chemical characteristics of the most important positive acute 
phase proteins in different animal species. 
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3. Selected acute phase proteins of clinical importance 
3.1 Haptoglobin 
The name haptoglobin (Hp) is derived from its ability to form a stable complex (haptein = to 
bind) with hemoglobin. Hp, an ǂ2-globulin with a molecular weight of approximately 125 
kDa, is one of the APPs in the blood of humans and animals and its concentration varies 
according to the health status (Whicher and Westacott 1992; Kushner & Mackiewicz, 1987). 
Hp was first described as a protein with the ability to increase the stability of the peroxidase 
activity of hemoglobin to low pH. Hp consists of light (ǂ) and heavy (ǃ) chains (ǂǃ)2, linked 
by disulfide bonds (Petersen et al., 2004). In humans, 16 different subtypes have been 
observed which have three different phenotypes, Hp 1-1, Hp 2-1 and Hp 2-2, with molecular 
weights of 100, 220 and 400 kDa, respectively (Putman, 1975). Porcine Hp has an 
electrophoretic mobility similar to that of human Hp phenotype 1-1; bovine Hp exists as a 
tetramer in association with albumin with a molecular weight above 1000 kDa in cattle 
serum which is most similar to human Hp 2-2 (Eckersall & Conner, 1990). Equine Hp 
consists of a pair of polypetides with molecular weights of 108 and 105 kDa. Dogs have only 
1 phenotyoe of Hp, which closely resembles human Hp 1-1 with molecular weight of 81 KD 
but the 2 ǂǃ chains are joined by a noncovalent interaction rather than by a disulfide bridge 
(the noncovalent linkage also exists in feline HP) (Petersen et al., 2004). 
The main function of Hp is to prevent the loss of iron via urine by the formation of a very 
stable complex with free hemoglobin. Hp together with hemopexin and transferrin helps to 
reduce the detrimental effects of free iron and to restrict the availability of free iron and to 
invading pathogens (Petersen et al., 2004). Free hemoglobin released from erythrocytes has 
oxidative and toxic properties (Putman, 1975). The Hp-hemoglobin complex is recognized 
via a specific cell surface receptor located on macrophages and when bound the complex 
will rapidly be removed from circulation.  Hp also inhibits bacteria dependent on hem iron 
for growth (Eaton et al., 1982). In cattle, Hp has been proposed to be involved in the 
regulation of lipid metabolism and as a immunomodulator. Stimulation of angiogenesis, 
role in lipid metabolism/development of fatty liver in cattle and inhibition of neutrophils 
respiratory burst activity have been proposed for Hp (Petersen et al., 2004). 
Hiss et al., (2004) showed that Hp in milk not only originates from serum Hp, which is 
produced by hepatocytes, but also from mammary glands in which Hp mRNA is expressed.  
Hp levels increase dramatically during infection, inflammation or trauma and measurement 
of its concentration in serum provides valuable diagnostic information to clinicians in both 
human and veterinary medicine. 
3.2 Serum amyloid A 
The SAA family was originally considered to comprise only a single circulating precursor of 
the amyloid A protein from which its name is derived. SAA constitutes a protein family 
related to the A proteins of secondary amyloidosis (Betts et al., 1991). The family is known to 
contain a number of differentially expressed apolipoproteins which can be divided into two 
main classes based on their responsiveness to inflammatory stimuli: acute phase serum 
amyloid A (A-SAA) and constitutive SAAs (C-SAAs). The A-SAAs are highly conserved 
across evolutionarily distinct vertebrate species and it is generally accepted that they have a 
crucial protective role during inflammation.  C-SAAs have been described in two species, 
human and mouse and are minimally induced during APR. Both SAAs associate with HDL.  
Multiple SAA genes and proteins have been described for several mammalian species 
(including human, mouse, hamster, rabbit, dog, mink, fox, cow, sheep, goat and horse) and 
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non-mammalian vertebrates (including marsupials and fish which provide evidence that 
they are likely to have important biological functions (Uhlar and Whitehead, 1999). 
The four human and five mouse SAA family members were originally named in numerical 
progression according to the order in which they were identified. According to the 
Nomenclature Committee of the International Society of Amyloidosis, extrahepatically-
produced SAA should be referred to as SAA3 (Sipe, 1999). The human SAA1 and SAA2 and 
the mouse Saa1 and Saa2 genes have 90 percent nucleotide identity (Betts et al., 1991) and all 
encode A-SAAs.  SAA3 show approximately 70 percent identity with SAA1 and SAA2 
(Kluve-Beckerman et al., 1986) but no mRNA or protein product specified by human SAA3 
has been identified. So human SAA3 protein, if it exists, cannot be a molecule with functions 
analogous to those of the SAA3 molecules in other species. The human SAA4 and the mouse 
Saa5 gene are the only constitutively expressed genes, which produce C-SAA (Uhlar and 
Whitehead, 1999). Intestinal epithelial cells, convoluted tubules of the kidney, bone marrow 
stromal cells, jejunal mucosa stomach, muscle, spleen, brain, heart, lung, ovary, testis, uterus 
and mammary glands are among the extrahepatic sites of A-SAA synthesis (Uhlar and 
Whitehead, 1999; McDonald et al., 2001). Different names have been used for SAA occurring 
in milk. Some authors refer to mammary-associated serum amyloid A as M-SAA 3 
(McDonald et al., 2001, Larson et al., 2005) while others use MAA (milk amyloid A) 
(O’Mahony et al., 2006; Safi et al., 2009). Many studies only use SAA regardless if it is 
hepatically or locally produced (Gronlund et al., 2003).  
The induction profiles of the SAA mRNAs in the liver and other tissues, vary considerably 
with different inflammatory agents. In humans, extra hepatic synthesis of both A-SAA and 
C-SAA mRNAs are expressed in monocytic/macrophages cell lines, endothelial and smooth 
muscle cells and also in adipocytes. These findings suggest a possible role for SAAs as an 
immunological defense molecule at local sites against inflammatory stimuli during the time 
taken to mount a systemic response by increased hepatic synthesis (Uhlar and Whitehead, 
1999). 
Like Hp, the biological function of SAA is not fully understood but it is known that SAA is 
involved in lipid transport /metabolism (Malle et al., 1993) and also in alteration of 
cholesterol metabolism under inflammatory conditions (Pannen & Robotham, 1995). SAA 
binds Gram-negative bacteria (Hari-Dass et al., 2005), possibly to facilitate the uptake by 
macrophages and neutrophils (Larson et al., 2005). Inhibitory effect on fever, on the 
oxidative burst of neutrophilic granulocytes and on in vitro immune response, chemotaxic 
effect on monocytes, PMN and T cells, and induction of calcium mobilization by monocytes 
and inhibition of platelet activation are among the functions attributed to SAA. Different 
conditions and diseases lead to increased SAA concentration in human, pig, cattle, horse, 
dog, cat, mouse, rabbit and chicken (Peterson et al. 2004,  Murata  et al., 2004), which will be 
addressed in the following sections.  
SAA is synthesized intraarticularly during inflammatory conditions, and this intraarticular 
SAA may lead to induction of metalloproteinase activity. The intraarticularly produced SAA 
isoform had a highly alkaline pI value, which is in accordance with pI values reported for 
extrahepatically synthesized murine and bovine SAA3 (Jacobsen et al., 2005). 
In chickens, SAA is likely to be a reliable APP for diagnosing inflammatory lesions 
(Chamanza et al., 1999). 
3.3 C-reactive protein (CRP) and serum amyloid-P component (SAP) 
CRP and SAP are pentraxins, belong to the highly conserved pentraxin family of plasma 
proteins with a pentameric organization of subunits (Steel and Whitehead, 1994).  
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Pentraxins are able to clear nuclear material released from necrotic tissue; they are also 
involved in opsonization, activation of classical pathway of complement (C1q),  
chemoattraction,  and  enhancement  of phagocytosis. CRP binds released bacterial or host 
DNA (Hirvonen, 2000). 
Canine AGP has been described as a very unusual protein of 43 KD with a very low pI of 
2.8-3.8 and a very high carbohydrate content of 45% (Ceron et al., 2005). 
CRP and SAP are found in all mammals and presumptive homologues have been found in a 
number of nonmammalian vertebrates and invertebrates (Steel and Whitehead, 1994).  CRP 
behaves like a broad-specificity antibody. It has been called an “ante” antibody, since it has 
been found in invertebrates that do not make either immunoglobulins or complement. It 
also is one of the key pattern recognition molecules that enable prompt host recognition of 
invading pathogens. In humans, CRP and SAP share only 51% amino acid identity and 59% 
nucleotide sequence identity (Steel and Whitehead, 1994).  
CRP is the first APP to be described as an APP in human. Crystallization of the CRP isolated 
from human serous fluids was first described in 1947. The crystalline protein was obtained 
from two pathological specimens, one a pleural fluid from a patient with streptococcal 
pneumonia and the other an abdominal fluid from a cirrhotic patient suffering from an 
intercurrent infection. CRP has been described in ruminants, dog, pig, rat, rabbit and to a 
lesser degree, horse (Petersen et al., 2004) and was originally named for its ability to bind the 
C-polysaccharide of Pneumococcus pneumonia. CRP has been shown to act as an opsonin for 
bacteria, parasites and immune complexes, can activate the classical pathway of 
complement, can modulate the behavior of several cell types, including neutrophils, 
monocytes, natural killer cells and platelets and can bind to chromatin, histones, and small 
nuclear ribonucleoprotein particles (snRNPs) (Steel and Whitehead, 1994). CRP increases L-
selectin shedding from neutrophils and prevents neutrophils-endothelial cell adhesion 
which leads to neutrophils release from marginated pool. CRP also stimulates monocytes to 
release an anti-inflammatory molecule, IL-1 receptor antagonist (IL-1Ra). Although CRP 
does not bind to normal cell membranes, it can  bind avidly to cells that are undergoing 
apoptosis or necrosis, through its ability to recognize the lysophosphatidylcholine (lysoPC) 
that appears on the surfaces of dying cells (Munford, 2000). 
SAP is a non-fibrillar plasma glycoprotein which is found in amyloid deposits due to its 
specific calcium dependent binding to motifs present on all types of amyloid fibrils. 
Amyloid deposits are present in a heterogeneous group of disorders, the amyloid A 
amyloidoses. The predominant amyloid A protein type found in amyloidotic tissues 
corresponds to the N-terminal two thirds of A-SAA (the first 76 residues of mature human 
A-SAA) (Uhlar and Whitehead, 1999). The SAP is also found to prevent fibrillar breakdown 
by enzymes and seems to be one of the factors that maintains the stability of the amyloid 
deposits. It interacts with inflammatory and complement factors and might be associated 
with the production of inflammation in specific cases. SAP concentration does not change in 
cattle, human, rat and rabbit during inflammation but normal level as well as acute phase 
concentration changes of SAP differ strongly between different mouse strains (Petersen et 
al., 2004). The exact role of SAP is uncertain. 
3.4 Alpha-1-acid glycoprotein (AGP) 
AGP is a sialo-glycoprotein synthesized and secreted mainly by hepatocytes and is the main 
protein component in seromucoid, the fraction of plasma that is most resistant to acid 
precipitation (Ceron et al., 2005).  
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Human AGP is characterized by low molecular weight (41–43 kDa), high solubility, very 
low pI (2.8–3.8) and high percentage of carbohydrates (45%). Its glycosylation pattern is very 
variable (12–20 glycoforms) depending on the physiological or pathological conditions, such 
as pregnancy, inflammation or cancer (Paltrinieri, 2008). 
AGP is considered a moderate APP in most species and is more likely to be associated with 
chronic conditions rather than acute inflammation. 
AGP is mostly synthesized during inflammation in rat, rabbit, mouse, man, cat, dog, horse 
and cattle but mammary-associated AGP has also been identified in bovine colostrum and 
milk (Ceciliani et al., 2005).  
AGP is a immunocalin; a group of proteins that shows significant immunomodulatory 
effects (Logdberg and Wester, 2000). AGP regulates the inflammatory response of leucocytes 
(e.g., inhibits platelet aggregation, proliferation of lymphocytes and activation of 
neutrophils (Hochepied et al., 2003). Immunomodulating effects of AGP are primarily 
downgrading the local inflammatory response to reduce tissue damage caused by 
inflammatory cells (Hochepied et al., 2003). Suppression of cattle leucocytes was also found 
to correlate with AGP concentrations during mastitis (Sato et al., 1995). One of the many 
functions of AGP is to protect cells from apoptosis, and an anti-apoptotic effect on cattle 
monocytes has recently been reported (Ceciliani et al., 2007). There is  some evidence that 
AGP might contribute to the net charge on microvessel walls and could decrease albumin  
leakage  from  circulation  during the acute phase. In cattle, AGP is known to suppress 
lymphocyte blastogenesis and thus possess immunosuppressive properties (Sato et al. 1995). 
Systemic AGP has two major physiological functions: drug binding and 
immunomodulation. Like serum albumin, AGP binds with and carries endogenous and 
exogenous substances such as heparin, histamine, serotonin and steroids. This ability might 
help to keep total drug binding levels unaffected in APR in which serum albumin decreases 
in concentration. AGP may help to enhance the clearance of lipopolysaccharide (LPS) by 
binding with it and neutralizing its toxicity (Murata et al., 2004). 
3.5 Fibrinogen (Fb) 
Fibrinogen is a soluble ǃ-globulin present in the plasma of all vertebrates. It is composed of 
3 nonidentical polypeptide chains linked by disulfide bridges and a glycoprotein that 
contains 3-5% carbohydrates. Fb specifically binds to CD11/CD18 integrins on the cell 
surface of migrated phagocytes, thereby triggering a cascade of intracellular signals that 
lead to enhancement of degranulation, phagocytosis, antibody-dependent cellular 
cytotoxicity and delay of apoptosis (Murata et al., 2003). Fb was one of the earliest 
recognized APPs. It is a coagulation protein produced by liver, serving as a matrix for 
wound healing (Raynes 1994). Fibrinogen is a minor APP in most species including humans 
and cattle and horse. Although determination of plasma Fb concentration has long been 
used for detecting inflammatory diseases, its relatively slow reaction during inflammatory 
insult hampers its clinical utility. Nevertheless, Fb measurements are easy and inexpensive 
to perform, and this fact has likely secured its continued wide use in veterinary medicine 
(Crisman et al., 2008). 
3.6 Negative acute phase proteins: albumin and transferrin 
Albumin is the most abundant protein in blood constituting the major band observed in 
serum protein electrophoretograms.  
Transferrin is a plasma glycoprotein that is responsible for the transport of iron in the 
circulation and has a single polypeptide chain of about 700 amino acids. It binds iron as a ferric 
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ion in 2 binding sites at a neutral pH (Ceron et al., 2005). Nutritional status affects production 
of negative APPs but the APR has a stronger effect than the nutritional plane on concentration 
of transferrin, albumin, and other negative APPs (Ceron et al., 2005). In mammals transferrin is 
down-regulated during inflammation (Kushner and Rzewnicki, 1999). 
Ovotransferrin in birds appears to have special characteristics differing from those of 
mammals. It has been shown that following injection of croton oil to induce inflammation a 
65-kDa glycoprotein with an N-terminal sequence matching to that of chicken 
ovotransferrin, a major egg white protein is induced. In laying hens, ovotransferrin is 
synthesized under the control of estrogen (Palmiter et al., 1981) and is a major constituent of 
egg white. Its major physiological function, like other members of the transferrin family, is 
presumed to be iron transport, and its antimicrobial activities are probably related to its 
ability to sequester iron, an essential element for bacterial growth. However, unlike in 
mammals, in birds it appears to be a positive APP (Xie et al., 2002). 
Other APPs like proteinase inhibitors, ǂ1-antitrypsin, ǂ1-antichymotrypsin, ǂ2-
macroglobulin, mannan-binding lectin (MBL), ceruloplasmin, etc have been dexcribed as 
APPs in different species but have a less diagnostic importance. 
4. Methods of analysis 
Although inflammatory status can be measured indirectly by measuring serum 
concentrations of albumin, globulins and copper (kaneko et al., 2008), but more specific and 
sensitive methods to determine the status are based upon direct measurement of individual 
APPs. The development of assays to quantify APPs has been pioneered by a number of 
laboratories throughout the world, in which calibration of the assays has been achieved by 
isolation of the protein and determinations of its concentration prior to its use as a standard 
(Skinner, 2001). The European Commission Directorate General Research Concreted Action 
Group was established in 2000 to harmonize the calibration of APP assays and to 
disseminate strategic and applied research results on the use of these assays. For those 
laboratories that are unable to set up specific and sensitive methods for APP measurement, 
electrophoresis on agarose or cellulose acetate gels can be used to identify changes in APP 
concentrations during inflammation or infection. (Carapeto et al., 2006). 
4.1 Haptoglobin 
Assays for serum Hp concentration can be divided into 2 groups: a) spectrophotometric 
assays and b) immunoassays. Although some ELISA assays have been established for Hp 
measurement, the convenience of methods based on the binding of Hp to hemoglobin and 
the potential for the development of automation, has lead to biochemical Hp assay 
becoming a routine biochemical test in many veterinary diagnostic laboratories. 
Spectrophotometric assays have been based on ability of Hp to bind hemoglobin, forming 
Hp-Hb complexes that either alter the absorbance of Hb in proportion to the concentration 
of Hp or preserve peroxidase activity at an acidic pH (Ceron et al., 2005). An automated 
spectrophotometric multispecies assay based on the peroxidase activity of Hp-Hb 
complexes has been described and validated by Eckersall et al., (1999), in which interference 
by serum albumin is eliminated. The methodology has been developed into a commercial 
biochemical assay kit for routine analysis, giving satisfactory results.  
Nephelometric immunoassays, in which the rate of precipitation of the Ab-Ag complex is 
measured, have been validated for Hp measurement in dogs (Ceron et al., 2005) and pigs 
(Lipperheide et al., 1998). Other methods for estimation of serum Hp include capillary zone 
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electrophoresis, turbidimetry (Ekersall, 2000), biosensor assay (Åkerstedt et al., 2006), single 
radial immunodiffusion (SRID) (Hanzawa et al., 2002), latex agglutination test (In Murata et 
al., 2003) and capillary zone electrophoresis (Pirlot et al., 1999). Most of these assays depend 
on the cross reactivity of antiserum to human Hp with the analogus protein in animal serum 
and must be properly validated before use.  
Canine serum samples must be diluted in many cases when Hp assays developed for other 
species are used, as the concentrations of Hp in health and disease are significantly higher in 
dogs than in other species (Ceron et al., 2005). 
Other methods of liquid phase analysis with the option of recycling of the sample (Philips, 
2001), such as those possible with Surface Plasmon Resonance (Biacore system), have been 
tested for Hp in bovine milk (Ǻkerstedt et al., 2005). 
Bovine serum Hp has been traditionally analyzed indirectly by measurement of Hb bound 
to Hp (Makimura & Suzuki 1982). Morimatsu et al. (1992) introduced a single radial 
immunodiffusion assay for bovine serum Hp.  Monoclonal antibodies against bovine Hp 
have been characterized and used for analysing bovine serum Hp by several 
immunotechniques (Hirvonen, 2000). 
4.2 Serum amyloid A 
Previously, SAA measurements were primarily the domain of research laboratories. 
Nowadays there are several methodologies for SAA measurement in different species. 
Monoclonal antiserum against human SAA has been used in a sandwich ELISA that can be 
used successfully for other species as well. An ELISA for equine SAA using 
chemiluminescent substrate has been established. Other methodologies for measurement of 
equine SAA include slide-reversed passive latex agglutination, latex agglutination 
immunoturbidimetric assay. A commercially developed immunoturbidimetric assay for 
human SAA has been evaluated for use in horses with good precision (Crisman et al., 2008). 
A commercially available ELISA for SAA measurement in veterinary species using 
monoclonal antiserum against human SAA has been proven to be useful for canine and 
feline SAA quantification (Ceron et al., 2005). Multispecies SAA kit has been developed by 
Tridelta Development Ltd which is suitable for most species except murine. 
Bovine SAA can be analyzed immunologically, and enzyme-linked  immunosorbent  assays 
(ELISA)  for the determination of bovine SAA have been developed (Boosman et al. 1989; 
Horadagoda et al. 1993). 
Other methods include electroimmunoassay, single radial immunodiffusion (SRID) and a 
sandwich enzyme immunoassay (Hultén et al., 1999). 
4.3 C –reactive protein 
Measurement of serum CRP is generally performed by immunoassays using species-specific 
CRP antibodies with several formats such as immunoturbidimetric assay, ELISA, 
slide/capillary reverse passive latex agglutination test, and time-resolved fluorometry 
(TRFIA) (Ceron et al., 2005). There is a commercially available automated turbidometric 
immunoassay for human serum CRP which has been validated for measuring canine CRP; 
however, in other investigations very weak cross-reactivity of canine CRP with antihuman 
CRP antibodies has been found (Ceron et al., 2005). Different nephelometry systems are 
compared during application for human CRP (Maggiore et al., 2005). Turbidimetry is 
developed for CRP in the dog (Kjelgaard-Hansen et al., 2003).  
A protein chip has been developed for measurement of haptoglobin and SAA in human 
patients (Tolson et al., 2004).  
www.intechopen.com
 
Acute Phase Proteins – Analysis, Clinical Applications and Potentials 
 
363 
4.4 Alpha-1-acid glycoprotein (AGP) 
Although AGP can be estimated by precipitation of the majority of serum proteins by 
perchloric acid and quantification of the remaining soluble proteins, AGP is measured 
routinely by single radial immunodifffusion (SRID) on agarose gel impregnated with anti-
species AGP rabbit serum (Tamura, 1989). The kits are species-specific and are available for 
humans, dogs and cats but have the disadvantage of time consuming process (24 to 48 hours 
to be complete). Immunoturbidimetric assays for canine and feline AGP have been 
developed that are rapid and adaptable to biochemical analyzers (Ceron, et al., 2005). 
Nephelometric and turbidometric immunoassay methods have been also described for AGP 
measurement (Komine et al., 1994). 
Preliminary experiments with a monoclonal anti porcine CRP and pig acute phase sera 
using protein microarray methodology on slides (Timmerman et al., 2004), offered the 
possibility to measure more than 1000 pig blood sample spots on a single slide. 
 In chickens, AGP is an APP of clinical significance. High AGP levels have been observed in 
chickens with various bacterial or viral pathogens (Murata et al., 2004).  
4.5 Ceruloplasmin 
Many quantitative methods based on different principles have been used for Cp 
measurement in plasma or serum. Assays based on oxidation of different compounds such 
as p-phenylenediamine (PPD) or its N-dimethyl derivative and o-dianisidine 
dihydrochloride have been used most often in veterinary medicine. Manual and automated 
methods based on PPD-oxidase activity have been reported for measuring Cp (Ceron et al., 
2005). Ceruloplasmin can also be estimated biochemically by measuring its endogenous 
oxidase activity.  
One of the main problems with Cp assays is the lack of commercially available reference 
materials to standardize Cp measurements (Ceron et al., 2005). 
4.6 Fibrinogen 
Fibrinogen (Fb) is a large protein of 340,000 Da, which constitutes about 5% of the total 
proteins of plasma. It is most simply and rapidly estimated by the heat precipitation-
refractometer method proposed by Kaneko and Smith in 1967. The heat precipitation 
method is now extensively used as a routine screening method but more accurate methods 
include modifications of the Ratnoff-Menzie assay, measurement of clot weight, and 
immunoprecipitation method (Crisman, et al., 2008). 
4.7 Methods of analysis: alternatives 
Indirectly, acute phase protein formation may be measured in biopsies by methods to assess 
upregulation of protein synthesis (quantitative PCR) (Gruys et al., 2005). 
A possible future challenge for veterinarians would be the development of high throughput 
techniques, such as protein microarray methodology, which would allow simultaneous 
measurements of thousands of samples per batch, as has already proposed for some species 
(Gruys et al., 2005). In addition, techniques able to detect qualitative or structural changes to 
the APPs, such as two-dimensional gel electrophoresis, high performance liquid 
chromatography (HPLC), Western blotting and lectin staining, are available (Paltrinieri, 2008). 
Although these techniques are currently used mainly for research purposes due to high cost 
and to the need for specialized equipment and trained personnel but they  may have crucial 
importance in diagnostics in the future if done rapidly, and at low costs, making it possible 
to run many samples at the same time. 
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5. Clinical applications of major APPs 
APP concentrations are elevated in many diseases with different pathogeneses. The fact cause 
APPs to have poor specificity in detecting the cause for a particular disease but some studies 
have been performed to increase the specificity of  APPs, using group analysis of APPs (acute 
phase index) (Gruys et al., 2005). On the other hand APPs have very high sensitivity in 
detecting different conditions that cause subclinical infection or inflammation. So APPs can 
provide 1) an alternative means for monitoring animal health, as well as for human patients 2) 
an objective information about the presence and extent of ongoing lesions in individual 
animals, 3) an information about the prevalence of a disease/diseases indicated by the high 
serum concentration of selected APP(s),  4) a prognostic tool, with the magnitude and duration 
of the APR reflecting the severity of infection (Petersen et al., 2004), 5) a practical means to 
identify the effectiveness of antibiotic therapy (Wittum et al., 1995), 6) a useful tool for 
separation of suspect from non-suspect animals during ante mortem inspection at 
slaughterhouses, to improve food safety for public health (Toussaint et al., 1995).  
A further likely use of the APPs as diagnostic markers in production animals is that they 
might have a role to play in monitoring health for optimal growth, by detection of small 
changes in APPs concentrations, using acute phase index (Toussaint et al., 1995).  
The interpretation of APP results from haemolytic, icteric and lipaemic samples should be 
interpreted with caution, due to the possible influence of these interfering substances on 
analytical results (Ceron et al., 2005). 
5.1 Acute phase proteins in human medicine 
Shortly after it was discovered that a protein in human serum binds to the pneumococcal 
“C” polysaccharide, Arvey and others found that the serum concentrations of this “C-
reactive” protein (CRP) can rise dramatically during illness. Although ESR, an indirect 
measure of APR, had been introduced as by Westergren in 1921, but its wide reference 
interval, moderate specificity and sensitivity, low to moderate reproducibility, being time-
consuming to be complete and the fact that its results may be affected by gender, age, 
temperature, drugs,  level of plasma proteins and RBC factors (hematocrit, morphology, 
size,…) (Collares and Vidigal, 2004) made it unsuitable to be a marker of choice for 
monitoring inflammation or infection; however it is a simple and inexpensive laboratory 
test. 
While plasma levels of CRP in most healthy subjects is usually 1mg/L with normal being 
defined as <10 mg/L (0.06-8 mg/L) its concentration is exponentially increases  
(100-500 mg/L), doubling every 8-9 hours and remains elevated during APR. So serial CRP 
measurements can be used as a diagnostic tool for infection, monitoring of treatment or 
early detection of relapse in humans.  
Today, CRP remains an APP of primary interest in humans, where it is a major marker of 
infection, autoimmune disease, trauma, malignancy, and necrosis including myocardial 
infarction. Furthermore, CRP has been proposed as a marker for wellness assessments, which 
is a common role proposed in many studies of human and animal APP (Cray et al., 2009). 
CRP levels serve as an early marker of the magnitude of inflammation in events as 
dissimilar as appendicitis and myocardial infarction. The level of circulating CRP correlates 
with endovascular disease and may serve to identify otherwise asymptomatic patients at 
sufficient cardiovascular risk to warrant aggressive therapy. Determining whether CRP has 
a direct pathologic role in the vascular wall itself may have the most clinical relevance 
(Zimmerman et al., 2003). Measurements of plasma or serum C-reactive protein can help 
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differentiate inflammatory from noninflammatory conditions and are useful in managing 
the patient’s disease, since the concentration often reflects the response to and need for 
therapeutic intervention. In some diseases, such as rheumatoid arthritis, serial 
measurements of C-reactive protein are of prognostic value (Gabay and Kushner, 1999). Lau 
et al., (2006) reported that levels of CRP were associated with HIV disease progression 
independent of CD4 lymphocyte counts and HIV RNA levels. Increased serum CRP level 
has been described to be associated with unstable angina or myocardial infarction, stroke, 
infection with C. pneumoniae, cytomegalovirus, hepatitis A, Herpes simplex, rubella virus, 
Helicobacter pylori, and E.coli lipopolysaccharide (Munford 2000), post-operative infection 
(Mustard et al., 1987), and heterotopic ossification (Sell and Schleh, 1999). 
 
 
 
Modified from Dixon (1983) and Pepys & Hirschfield (2003). 
Table 5. CRP response in human diseases 
Larsson et al., (1992) performed a prospective study focused on CRP levels in 193 patients 
undergoing 4 types of uncomplicated elective orthopedic procedures and concluded that a 
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normalized CRP response that follows a typical biphasic response indicate an uneventful 
recovery. Meyer et al. (1995), proposed using CRP as a simple, reliable, and inexpensive 
screening test in detection of early infections after lumbar microdiscectomy. CRP levels are 
increased in patients with rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing 
spondylitis and psoriatic arthritis, giant cell arthritis and rheumatic polymyalgia (Rosa Neto 
and Carvalho, 2009). CRP can be used as a tool to monitor the effect of antibiotic therapy 
(Peltola et al., 1984). 
There is a wealth of literature supporting the use of CRP in the diagnosis and monitoring of 
treatment of infection in post-operative patients but it should be noted that single CRP 
reading has very limited value, and that a trend should be followed to have the full 
usefulness of CRP measurement. The exquisite responsiveness of CRP to acute phase 
stimuli, along  with its ease of measurement, have led to CRP levels being used to monitor 
accurately the severity of inflammation and the efficacy of disease management during an 
infection. Covering all related studies is out of the scope of this chapter and readers are 
referred to review articles for more detailed information (Steel and Whitehead, 1994). Table 
5 summarizes CRP response in different human diseases.  
In humans, SAA is catabolized in the liver and has a half-life of 1 day but the capacity of the 
liver to degrade SAA decreases in acute or chronic inflammation (Ceron et al., 2005). SAA is 
a major APP in humans and has been reported to be as part of the host innate immune 
defense mechanisms against HCV infection. SAA was also shown to be an opsonin for 
gram-negative bacteria (Cai et al., 2007). The highest concentrations of SAA are generally 
found in connection with bacterial infections, but SAA has also proven useful as a marker in 
many other clinically important conditions in human medicine, including viral infections, 
rheumatic disorders, and neoplastic disease (Hulten et al., 1999).  SAA has been found 
valuable in monitoring viral infections such as influenza and rhinovirus in human medicine 
(Petersen et al., 2004). However, due to difficulties in standardization and a need of more 
complicated and time-consuming assays compared with CRP, SAA has not yet gained full 
acceptance as an inflammatory marker in clinical practice (Hulten et al., 1999). 
SAA and SAP have been implicated in a number of clinical conditions like secondary or 
reactive amyloidosis that is the occasional consequence of a variety of chronic and recurrent 
inflammatory diseases, for example leprosy, tuberculosis, systemic lupus erythematosis and 
rheumatoid arthritis (Steel et al., ).  Pepys et al., (2004) have developed a drug that is 
competitive inhibitor of SAP binding to amyloid fibrils. The mechanism may provide a new 
therapeutic approach to both systemic amyloidosis and associated diseases, including 
Alzheimer’s diseases and type 2 diabetes. The association of SAA with HDL3 suggests 
another area in which chronically high SAA concentrations may promote clinical disease. 
The sustained decrease in total HDL during the acute phase, could be a major risk factor for 
the development of atherosclerosis in patients with chronic recurrent inflammation (Steel 
and Whitehead, 1994). 
There is an extensive body of reports concerning SAA responses in naturally occurring 
infectious and noninfectious inflammatory conditions, especially in humans, that has been 
reviewed by Malle and De Beer (1996).  
Some investigators have advocated caution when using SAA in clinical cases in human 
medicine, stating that the highly sensitive and unspecific nature of the SAA response could 
lead to misjudgment of the severity of clinical conditions (Whicher et al., 1985). Zhao et al., 
(2009) in a meta-analysis and systematic review found that SAA levels are positively 
associated with BMI levels and that weight loss led to decreased SAA levels. Many studies 
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had been conducted on the relationship between SAA and deposition of reactive (AA) 
amyloid in patients with chronic arthritis, tuberculosis or Familial Mediterranean Fever 
(Gruys et al., 2005). 
One of the most interesting features of AGP is that, not only is its gene expression up-
regulated during an acute phase reaction, but the activity of the protein can be further fine-
tuned by qualitatively controlling its post-translational processing by modifying its glycan 
microheterogeneity and, perhaps, also its phosphorylation status (Ceciliani and Pocacqua, 
2007). 
An elevated plasma haptoglobin level is seen following inflammation, trauma, and burns 
and with tumors. The plasma level increases 4 to 6 days after the beginning of inflammation 
and returns to normal 2 weeks after elimination of the causative agent. The plasma 
haptoglobin level in the initial phase of acute myocardial infarction is high, but later, owing 
to hemolysis, the plasma level decreases temporarily. The plasma haptoglobin level is 
decreased in hemolysis, malnutrition, ineffective erythropoiesis, hepatocellular disorders, 
late pregnancy, and newborn infants. In addition, the plasma haptoglobin level is lower in 
people with positive skin tests for pollens, high levels of IgE and specific IgE for pollens and 
house dust mites, rhinitis, and allergic asthma (Sadrzedeh and Bozorgmehr, 2004). The 
possible association of allelic polymorphism of haptoglobin with various pathologic 
conditions such as coronary artery disease, hematologic disorders, infectious diseases and 
other disorders has been studied in detail by Sadrzadeh and Bozorgmehr (2004). 
5.2 Acute phase proteins in canine medicine 
CRP is a major APP in dogs and its serum concentration can increase rapidly from <1mg/L 
to >100 mg/L in a number of conditions including surgical trauma, rheumatoid arthritis, 
polyarthritis, intestinal obstruction, inflammatory bowel disease, lymphoma, acute 
pancreatitis, pyometra, pneumonia, bacterial enteritis, turpentine oil injection, E.coli 
endotoxemia, babesiosis, leishmaniosis, leptospirosis, parvovirus infection, trypanosomiasis, 
Bordetella bronchiseptica and B.canis and Ehrlichia canis infection, bacterial and hemorrhagic 
enteritis and tumors (Ceron et al., 2005; Jergens et al., 2003 and Tecles et al., 2005, 
Yamamoto, et al., 1993). CRP levels increase from mid-gestation in pregnant bitches, 
coinciding with embryonic implantation (Eckersall et al., 1993; Vannucchi et al., 2002).  
Burton et al., (1991) showed a significant, but weak, correlation between CRP concentration 
and band neutrophils count and concluded that CRP could be more indicative of the extent 
of the inflammatory lesion. There is no circadian rhythm in CRP concentration in dogs 
(Otabe et al., 1998).  
In a review of more than 900 cases of inflammation in dogs with various diseases, CRP 
concentrations were significantly correlated with disease, whereas only slight or no 
correlation was found with total WBC and band neutrophil counts (Ohno et al., 2008). 
Hp is a moderate APP in dogs and is particularly sensitive to the effects of corticosteroids. 
This fact should be considered when Hp is used for monitoring inflammation as steroid 
treatment or hyperadrenocorticism interfere with test result. In canine hyperadrenocorticism 
a moderate increase occurs in serum Hp levels, probably due to endogenous glucocorticoid-
mediated stimulation of Hp production (Ceron et al., 2005). Serum Hp levels have been 
shown to increase in dogs with leishmaniosis, trypanosomiasis, diabetes mellitus and 
diabetic ketoacidosis, and Cushing’s syndrome (Ceron et al., 2005).   
The reference intervals proposed for serum canine Hp are 0-3 and 0.3-1.8 g/L (Ceron et al., 
2005).  
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SAA, a major APP in dogs, increases in the serum samples of dogs with leishmaniosis, 
parvovirus and Bordetella bronchiseptica infection. Serum and CSF concentrations of SAA are 
increased in dogs with steroid-responsive meningitis-arteritis (SRMA). In response to 
prednisolone therapy serum CRP and SAA concentrations fall within reference intervals; 
while in patients that relapse with SRMA, the concentrations increase. The use of APPs as 
biomarkers of remission and relapse of SRMA has proved less expensive and invasive than 
previous monitoring methods (Eckersall and Bell, 2010). Reference intervals for SAA 
concentrations in canine serum have been reported as nondetectable to 2.19 mg/L in one 
study and 1.15 ± 2.53 mg/L in another one (Ceron et al., 2005). 
AGP, a moderate APP in dogs, in a health screen was shown to be useful for identifying 
dogs with subclinical disease that, after 2 weeks, had clinical signs or even died of diseases 
such as parvovirus infection (Ceron et al., 2005). AGP has been reported to increase in 
diseases such as babesiosis, lymphoma, carcinoma, sarcoma, parvovirus and Ehrlichia canis 
infection (Ceron et al., 2005). Clinically healthy Yorkshire Terriers and Dachshunds have 
lower levels of AGP compared with Poodle, Cocker Spaniel, Labrador Retriever, or German 
Shepherd. This finding could explain the wide range of AGP values (40-1070 mg/L) in 
healthy dogs (Ceron et al., 2005). Different authors have been proposed different reference 
intervals for serum AGP concentrations in dogs 322 ± 202 µg/ml, 509 ± 117 µg/ml,  
302 ± 74 µg/ml, <380 µg/ml, 480 ± 149 µg/ml (Ceron et al., 2005). Phenobarbital, in a 
therapeutic dosage regime, induces a significant increase in canine AGP concentration, 
which should be considered during the interpretation of AGP results. Dogs with hepatitis or 
with turpentine treatment have raised serum AGP concentrations (Murata et al., 2004).  
5.3 Acute phase proteins in feline medicine 
Contrary to reports in other species, data regarding APP levels in cats are scarce and mostly 
focused on general aspects of feline APP biology, such as the demonstration of the lack of 
age-related changes in APPs concentrations in feline serum, basic and comparative 
information about APP gene and protein structures or methodological aspects of 
measurement of feline APPs (Paltrinieri, 2008). Most feline APP studies have been focused 
on AGP, SAA and Hp, the three major APPs in cats. AGP and Hp are considered as 
moderate APPs in cat by some authors. The peak time and magnitude of an APP response 
vary depending on the type of stimulus. Kajikawa et al., (1999) studied the changes in 
concentrations of SAA, AGP, Hp and CRP in feline sera following injection of 
lipopolysachharide or turpentine oil and showed a 4.2-, 5.7- and 2.9-fold increase in SAA, 
AGP and HP concentration, while CRP concentration didn’t show any significant change. 
The time of detecting a significant increase in concentrations of SAA, AGP, and Hp was 8, 24 
and 24 hours, respectively. Sasaki et al., (2003) found increases of >10-fold in AGP 
concentrations in cats with FIP and concluded that SAA and AGP could be considered as 
major APPs in the cat. Quantification of AGP has been demonstrated to be a reliable aid in 
the diagnosis of FIP, although not pathognomonic for the disease because high levels are 
also found in cats with feline immunodeficiency virus (Duthie, et al., 1997). Increases in 
other APPs (Hp and SAA) have been detected in FIP-infected cats. Increases in Hp 
concentration have been described in cats with abscesses and upper respiratory tract 
infections; while Hp concentration decreased after hemolysis caused by hemobartonellosis 
(Ceron et al., 2005). Concentrations of SAA, AGP, and Hp increased significantly 1 day after 
surgery in cats (Ceron et al., 2005).  
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Some feline pathological or pathophysiological conditions in which increases in APPs have 
been reported are as follows: 
Anemia of inflammatory diseases (localised purulent infections), diabetes, experimental 
inflammation, feline coronavirus (FCoV) infection (non-symptomatic), feline calicivirus 
infection, chlamydiosis, feline leukaemia virus, feline infectious peritonitis, feline 
immunodeficiency virus (FIV), hospitalization, infectious diseases (miscellaneous), injury, 
lymphoma , amyloidosis in Somali, Oriental and Abyssinian cats, renal failure, splenectomy, 
surgery, and tumors (Paltrinieri, 2008). 
The results of the studies on feline APPs indicate that Hp, SAA and, especially, AGP should 
be included in laboratory panels to diagnose inflammation in cats. 
5.4 Acute phase proteins in ruminant medicine 
Hp is a major APP in ruminants. Its serum level is negligible in healthy animals, but 
increases over 100-fold on immune stimulation (Conner et al., 1989).  
Bovine Hp was first documented by Bremner (1964) who reported that plasma samples from  
healthy calves contained very little Hp, and that local inflammation induced by injection of 
turpentine elevated Hp concentrations greatly. In healthy cattle the serum concentration is 
below 20 mg/L but it can increase in concentration to over 2 g/L within a couple of days of 
infection (Eckersall and Bell, 2010). Many studies have indicated the significance of Hp as an 
clinically effective marker for evaluating the presence, severity and recovery of cattle with 
trauma, inflammation, experimental and natural inflammatory diseases, foot and mouth 
disease, fatty liver (hepatic lipidosis), mastitis, pneumonia, enteritis, peritonitis, 
endocarditis, abscesses, endometritis, clinical respiratory tract disease, bacterial 
contamination of uterus and delayed uterine involution, infections with Mannheimia 
haemolytica, Pastuerella multocida, bovine viral diarrhea (BVD) virus, bovine herpes virus 1 
and bovine respiratory syncytial virus  (Murata et al., 2004, Petersen et al., 2004). Hp is also a 
useful marker for monitoring processes such as tail docking and surgical castration. 
Elevations have also been reported in cows at parturition, during starvation and following 
the stress of road transport (Eckersall, 2006). Alsemgeest  et al. (1994)  found a  significant 
difference (P<0.001) in Hp levels between healthy animals and animals with inflammatory 
diseases. Godson et al., (1996) and Young et al. (1996) found Hp to be a valuable diagnostic 
aid in bovine respiratory disease (BRD), and Wittum et al. (1996) suggested Hp to indicate 
response of respiratory tract disease to antimicrobial therapy (In: Hirvonen, 2000). Hp is 
used to monitor the treatment efficacy of antibiotics in cows with toxic puerperal mastitis. 
Hp is also used to determine the effect of anti-inflammatory drugs following the castration 
of bull calves, the effects of treatment in transport-stressed feedlot cattle, and the changes in 
the blood profile of neonatal calves (Murata et al., 2004). Hp can be used to investigate the 
relationship between uterine involution and the presence of intrauterine bacteria in ewes; 
however, Hp levels remained unchanged following castration or tail-docking in lambs 
(Murata et al., 2004). 
Scott et al. (1992) reported serum Hp to have prognostic value in ovine dystocia cases, where 
serum Hp concentration of above 1.0 g/L indicated a reduced survival rate (Hirvonen, 2000).  
In cattle SAA has been identified as a marker of inflammation being elevated more in acute 
rather than chronic conditions. It was raised also by experimental infection with Mannheima 
haemolytica, with bovine respiratory syncytial virus and in experimental and natural cases of 
mastitis ((Eckersall, 2006). SAA is a valuable APP in diagnosing cattle with inflammation 
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(Murata et al., 2004). Elevated SAA levels are also found in conditions unrelated to 
inflammation, in cows at parturition or in cattle subjected to physical stress (Murata et al., 
2004). 
When screening dairy cow herds, SAA was found to reflect systemic inflammatory disease. 
A good agreement (i.e. high specificity) between ruling out inflammation by a clinical 
examination performed by field veterinarians and SAA negative serum samples was 
observed (Höfner, 1994). 
5.4.1 Bovine APPs: detection of mastitis and subclinical mastitis 
The most important and common disease among dairy cows is mastitis and is still a big 
challenge for the dairy industry all over the world. There are two forms of mastitis: a) 
clinical, which is often easy to detect and b) subclinical mastitis, which shows no visible 
changes in the udder or in the milk and should be detected through different diagnostic 
tests including somatic cell count (SCC), California mastitis test, electroconductivity, 
measurement of lactose, LDH, alkaline phosphatase, plasminogen, NAGase, pH, lactate, 
alpha-1-antitrypsin, etc in milk.The most common way to detect subclinical mastitis is by 
measuring the SCC. Since SCC is influenced by other factors than mastitis, including 
lactation number, stress, stage of lactation, etc., there is a need for new biomarkers for 
detection of subclinical mastitis (Akerstedt, 2008). A lot of research has been done to find the 
biomarker with high sensitivity and specificity for diagnosis of subclinical mastitis. Recently 
there has been an increased interest in the potential of APP in milk (Eckersall et al., 2001; 
Grönlund at al., 2003; Petersen et al., 2004; Pyörala, 2003; Jacobsen et al., 2005; Eckersall et 
al., 2006; O’Mahony et al., 2006; Hiss et al., 2007; Kováč et al., 2007, Safi et al., 2009). Hp 
serum concentrations increased in experimentally induced mastitis and in field infections of 
different etiology (Petersen et al., 2004). Serum amyloid A has also been found to be a 
marker of experimentally induced and naturally occurring mastitis (Petersen et al., 2004, 
Eckersall and Bell, 2010). It has been shown that SAA is also produced by the mammary 
gland epithelial cells and a mammary-associated isoform of SAA (SAA3) has been identified 
in milk (Akerstedt, 2008).  
The clinical accuracies of different tests such as CMT, SCC, SAA, serum Hp and Hp and 
SAA in milk for detection of subclinical mastitis have been studied and SAA in milk was 
shown to be the most accurate test for the diagnosis of subclinical mastitis with area under 
curve (AUC) of 0.998 (Safi et al., 2009). Most of the studies have suggested SAA and Hp as 
potential biomarkers for milk quality; so there is considerable potential for the use of a 
biological marker, such as SAA and Hp, which is present in milk and can be measured 
routinely, rapidly and reliably, for the objective and early diagnosis of mastitis. Such a 
marker could be particularly important for the continued development of robotic milking 
systems in which the manual examination of milk and cows is not practicable; it might also 
provide a more accurate and earlier diagnosis of intramammary infection, reducing the time 
to treatment, and thus possibly reducing the adverse effects of mastitis in both economic 
and welfare terms (Eckersall et al., 2001). 
5.5 Acute phase proteins in equine medicine 
Equine SAA is an acute phase apolipoprotein that increases over 100 fold after tissue injury, 
infection, or inflammation. Hepatocytes are the main source of SAA synthesis, but 
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extrahepatic production of several isoforms of SAA (specifically SAA3, has been 
demonstrated in the mammary gland and synovial fluid of horses (Jacobsen et al., 2006, 
Mcdonald et al., 2001).  
SAA has been shown to be a sensitive marker of inflammation and its increased 
concentrations have been reported in foals with various bacterial infections, septicemia, 
localized infections and arthritis (Crisman et al., 2008). It is generally agreed that SAA 
determinations proved superior when compared with classical markers of inflammation (Fb 
and leukocyte counts) in distinguishing infectious from noninfectious causes of systemic 
inflammatory response syndrome (SIRS) (Crisman et al., 2008). Increased levels of SAA has 
been shown in surgical trauma, experimental aseptic arthritis, equine herpes virus serotype 
1 and Streptococcus equi, equine influenza virus serotype A2, infectious arthritis, 
tenovaginitis, experimental infection with equine herpes virus, various infections in foals 
and experimentally induced arthritis (Petersen et al., 2004), Rhodococcus equi pneumonia and 
colic. Jacobsen and Andersen in their excellent paper (2007) reviewed different conditions 
that result in increased equine SAA. 
The reference range of SAA in clinically healthy adult horses reported as <7 mg/L in one 
study (Hulten et al., 1999) and <0.5 to 20 mg/L in other ones (Crisman et al., 2008). Due to 
the short half-life of SAA, sequential SAA measurements could be potentially useful in 
patient management and prognostication. 
Hp, a moderate APP in horses, increases during infection, stress, trauma, allergy, surgery, 
noninfectious arthritis, rhabdomyolysis, traumatic incidents, colic, enteritis, grass sickness, 
castration,  inhalation of equine influenza virus, experimental local aseptic inflammation  
and carbohydrate-induced laminitis (Petersen et al., 2004) while a substantial decline in 
serum concentration of free Hp is seen during intra- or extravascular hemolysis. The 
reference interval of serum Hp is 2-10 g/L (Crisman et al., 2008). 
Little work has been done on AGP in horses. Increased AGP levels has been reported in 
colts 2 to 3 days after castration, in adult horses after jejunostomy and in ponies fed with 
high carbohydrate diets result in laminitis (Crisman et al., 2008).  
CRP has been reported to increase in horses with pneumonia, enteritis, and arthritis, 
carbohydrate induced laminitis and also following intramuscular injection of turpentine 
(Petersen et al., 2004).  
Fibrinogen has a wide reference interval in healthy horses (2-4 g/L) and is a slow reacting 
APP, therefore Fb is considered a fairly insensitive APP. 
A limited and late response to stimuli with peak values 2-4 times normal concentration 4-6 
days after stimuli and a slowly declining concentration during recovery are the drawbacks 
of Fb in horses (Campbell et al., 1981). 
Measurement of major APPs in horses can provide an objective determinant of the heath, 
estimate the severity of underlying conditions and allow monitoring of the chosen therapy. 
5.6 APP in the meat industry 
One potential indication for the use of APP is to improve the quality of the meat inspection 
process. According to Saini & Webert (1991), incorporation of APP tests to ante mortem and  
post  mortem inspection process allows screening of all animals to identify those with disease 
activity, confirm presence of disease in suspect animals at ante mortem inspection, and 
confirm the presence of a systemic illness at post mortem inspection. For these purposes, the 
non-specific nature of the APR is a major advantage (Hirvonen 2000). With their low 
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specificity for a particular disease, the APP would not be used as a front line test for specific 
infection. However, as a screening tool for monitoring the general health and welfare of 
animals at slaughter the APP could be valuable and have potential advantages in being able 
to be adapted to assays of the required accuracy, precision and robustness (Eckersall, 2006). 
Public health is another concern affecting the introduction of APP tests to the meat industry.  
Control  of pathogens  that  are  able  to create  food-borne epidemics, like Salmonella, 
Listeria, E. coli, Toxoplasma, and Campylobacter are of specific interest. Furthermore, 
traditional meat inspection methods are not effective in detecting some other diseases, like 
tuberculosis or cysticercosis. On-line APP tests would improve the sensitivity of traditional 
meat inspection protocols and prevent the contamination of meat processing plants (Saini et 
al., 1991). 
Six-fold increases were found in Hp concentration comparing dairy cows with infectious, 
metabolic or traumatic disease at slaughter to those with only minor lesions. Another study 
showed a 40-fold increase in Hp and a 7-fold increase in SAA concentration between healthy 
beef cattle and dairy cattle culled with acute pathological lesions (Tourlomousis, et al., 2004). 
In calves to be slaughtered, haptoglobin concentration in serum indicates gross lesions at 
post mortem inspection (Young et al., 1996). In another study on emergency slaughtered 
dairy cows, a higher Hp concentration was observed (Hirvonen  et al., 1997). 
To detect cows with severe pathologic conditions, Tourlomousis et al. (2004) proposed 107 
mg/L and 0.18 g/L, as the cut off points for SAA and Hp, respectively. Safi et al., 
(unpublished data) studied serum SAA and Hp in healthy cows (n=30) and cows with 
different pathological conditions (n=50) and proposed 60 mg/L and 0.96 g/L, as the cut off 
points for SAA and Hp, respectively. Such results demonstrate a significant potential of 
APPs to help ante-mortem differentiation of “suspect” and “non-suspect” animals, which 
could enable use of a simplified postmortem inspection for the latter group. 
5.7 Acute phase index 
Because APPs vary in their response to inflammation and tissue damage, group analysis of 
APPs (serum APP profile) may be more meaningful than measuring a single protein 
(Eckersall, 1995). Use of APP profiles involving at least 1 major (CRP or SAA), 1 moderate 
(Hp, AGP, or Cp), and 1 negative APP are likely to become more widely used instead of the 
determination of individual APPs. Such an approach may improve the sensitivity of 
individual assays, as has been shown for canine leishmaniosis (Ceron et al., 2005). 
Calculation of an index from values of rapid- and slow-reacting positive and negative APPs 
has been repeatedly mentioned (Gruys and Toussaint, 2001; Gruys, 2002; Tousaint et al., 
1995, 2002, 2004; Niewold et al., 2003), because it appeared to increase statistical sensitivity 
and specificity for detecting non-healthy subjects (Gruys et al., 2005). Use of an acute phase 
index, by combining the results of both positive and negative APP has been suggested for 
differentiation of different pathogens that cause subclinical mastitis (Safi et al., unpublished 
data). 
6. Conclusion 
Early detection of systemic inflammation is essential to devise and implement an effective 
treatment plan. Early diagnosis of subclinical diseases that subsequently impair health and 
performance is of great importance in both humans and animals. So the search for early 
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markers of inflammation has been expanded in human and veterinary medicine over the 
past several decades.  
For production animals, monitoring APPs on a herd basis by including it in schemes for 
metabolic and nutritional profiling would be logical, not only for the identification of 
individual animals with disease, but also as a means to categorize the level of any sub-
clinical disease present. Conditions identified by APP investigation have been related to the 
hygiene level on farms and so have a direct bearing on animal welfare as well as health 
(Eckersall, 2004). 
APP may also serve in the follow-up of medical treatment, where sequential APP 
determinations  would  provide  accurate  information  of  the  course  of  the  disease. Early 
detection of subclinical diseases and, patient management and the monitoring of treatment 
would be more successful using APP analysis.  
The harmonization of assay calibration between laboratories around the world in order to 
produce comparable results has been started (Skinner et al., 2000) and has caused a major 
practical advance for the future prospects in the application of APP assays. 
Understanding better the basic pathophysiologic mechanisms by which APR is induced 
would help us to develop novel drugs that specifically block the proinflammatory effects of 
APPs. 
New discoveries on technological possibilities for rapid chemical multianalyses have a key 
role to widespread use of APPs in human and veterinary medicine as well as in animal 
production. The current advances which have taken place in proteomics could also identify 
low abundance APPs, not recognized up to now as the APPs currently measured have 
plasma concentrations in the mg/L to g/L range. If proteomic methods are used to examine 
serum protein in the ng/L or pg/L range then a host of new APPs may well be revealed 
(Eckersall, 2004). This could be a new era in APP research.  
At the present time there is a wealth of literature supporting the potential of APPs in the 
regular health monitoring of humans and animals. 
David Eckersall is right. “The time is right for acute phase protein assays” (Eckersall, 2004). 
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